References
- Mandell G, Bennett J, Dolin R. Principle and Practice of Infectious Diseases. 8th ed. Canada,Elsevier Saunders,PA19103-2899, Churchill Livingstone; 2014:2170–2175.
- Cha A, Budovich A. Sofosbuvir: a new oral once-daily agent for the treatment of hepatitis C virus infection. Pharm Therap. 2014;39(5):345–352.
- Cox-North P, Hawkins KL, Rossiter ST, et al. Sofosbuvir‐based regimens for the treatment of chronic hepatitis C in severe renal dysfunction. Hepatol Commun. 2017;1(3):248–255. doi:https://doi.org/10.1002/hep4.1035.
- Bhatia HK, Singh H, Grewal N, et al. Sofosbuvir: a novel treatment option for chronic hepatitis C infection. J Pharmacol Pharmacother. 2014;5(4):278–284. doi:https://doi.org/10.4103/0976-500X.142464.
- Izzedine H, Launay-Vacher V, Deray G. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis. 2005;45(5):804–817. doi:https://doi.org/10.1053/j.ajkd.2005.02.010.
- Saxena V, Koraishy FM, Sise ME, et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 2016;36:807–816. doi:https://doi.org/10.1111/liv.13102.
- Gentile I, Borgia F, Buonomo AR, et al. A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir. Curr Med Chem. 2013;20:3733–3742. doi:https://doi.org/10.2174/09298673113209990178.
- Paget GC, Barnes JM. Toxicity in evaluation of the drug activities. In: Laurence DR, Bacharach AL, eds. Pharmacometric. Vol. I. 1st ed. London, New York: Academic Press; 1964:1–13.
- Ding SP, Li JC, Jin CA. Mouse model of severe acute pancreatitis induced with caerulein and lipopolysaccharide. World J Gastroenterol. 2003;9(3):584–589. doi:https://doi.org/10.3748/wjg.v9.i3.584.
- Bancroft JD, Layton C. The hematoxylins and eosin. In: Suvarna SK, Bancroft JD, Layton C, eds. Bancroft’s Theory and Practice Histology Techniques. 8th ed. New York: Elsevier; 2018a:127–138.
- Bancroft JD, Layton C. Connective and other mesenchymal tissues with their stains. In: Suvarna SK, Bancroft JD, Layton C, eds. Bancroft’s Theory and Practice Histology Techniques. 8th ed. New York: Elsevier; 2018b:153–175.
- Hayat MA. Principles and Techniques of Electron Microscopy: Biological Applications. 4th ed. USA: Cambridge University Press; 2000:4–85.
- Tietz NW, Finley PR, Pruden EL. Clinical Guide to Laboratory Tests. 2nd ed. Philadelphia: W.B. Saunders; 1990:304–306.
- Mould RF. Introductory Medical Statistics. 3rd ed. Bristol, Philadelphia: Institute of Physics Publishing; 1998:18–27.
- Newman DJ, Price CP. Renal function and nitrogen metabolites. In: Textbook of Clinical Chemistry. 3rd ed. Philadelphia: WB Saunders Co.; 1999:1204.
- Knapp S, Lawner S, Abramowitz W. Statistic Using SPSS: An Integrative Approach. 1st ed. USA: Cambridge University Press; 2014:373–374.
- El Gharabawy GSH, Abdallah EEA, Kaabo HF, et al. Histological effects of sofosbuvir on the kidney of male albino rats and the possible protective role of vitamin C. Egypt J Hosp Med. 2019;76(1):3335–3354. doi:https://doi.org/10.21608/ejhm.2019.36898.
- Dashti- Khavidaki S, Khalili H, Nasiri-Toosi M. Potential nephrotoxicity of sofosbuvir-based treatment in patients infected with hepatitis C virus: a review on incidence, type and risk factors. Expert Rev Clin Pharmacol. 2018;11(5):525–529. doi:https://doi.org/10.1080/17512433.2018.1451327.
- Duque JC, Dejman A, Venkat V, et al. Acute interstitial nephritis following treatment with direct-acting antiviral agents in hepatitis C virus-infected patients: a case series. Clin Nephrol. 2021;95(1):22–27. doi:https://doi.org/10.5414/CN110276.
- Issa NM, El-Sherif NM. Light and electronic histological studies to the effect of sofosbuvir on the visual cerebral cortex of adult male albino rat. J Am Sci. 2017a;13:79–87.
- Issa NM, El-Sherif NM. Histological and immunohistochemical studies on the cornea and retina of sofosbuvir treated rats. Austin J Anat. 2017b;4(2):1-4. id1068.
- Dina BF, Dalia AE, Zeinab AS. Alveolar process changes associated with administration of nucleos (t)ide analogue (sofosbuvir) in rat model. Dent Med Probl. 2018;55(1):11–16. doi:https://doi.org/10.17219/dmp/81592.
- Edelstein CL, Ling H, Schrier RW. The nature of renal cell injury. Kidney Int. 2006;51:1341–1351. doi:https://doi.org/10.1038/ki.1997.183.
- Kohler JJ, Hosseini SH, Hoying-Brandt A, et al. Sofosbuvir renal toxicity targets mitochondria of renal proximal tubules. Lab Invest. 2009;89:513–519. doi:https://doi.org/10.1038/labinvest.2009.14.
- Prasad N, Patel MRA, Pandey A, et al. Direct acting antiviral agents in hepatitis C virus-infected renal allograft recipients: treatment and outcome experience from single center. Indian J Nephrol. 2018;28(3):220–228. doi:https://doi.org/10.4103/ijn.IJN_190_17.
- Stedman C. Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential. Therap Adv Gatroenterol. 2014;7:131–140. doi:https://doi.org/10.1177/1756283X13515825.
- Feng JY, Xu Y, Barauskas O. Role of mitochondrial RNA polymerase in the toxicity of nucleotide inhibitors of hepatitis C virus. Antimicrob Agents Chemother. 2015;60:806–817. doi:https://doi.org/10.1128/AAC.01922-15.
- Cornella SL, Stine JG, Kelly V, et al. Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: a case series. Postgrad Med. 2015;127(4):413–417. doi:https://doi.org/10.1080/00325481.2015.1021660.
- Mendizabal M, Reddy KR. Chronic hepatitis C and chronic kidney disease: advances, limitations and unchartered territories. J Viral Hepat. 2017;24:442–453. doi:https://doi.org/10.1111/jvh.12681.
- Brown PR, Omar S, Alexander W, et al. Acute kidney injury in patients undergoing chronic hepatitis C virus treatment with Ledipasvir/Sofosbuvir. Hepatol Commun. 2018;2:1172–1178. doi:https://doi.org/10.1002/hep4.1243.